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Abstract 
Background: The present study aimed to evaluate the influence of the magnitude of best tumor 
shrinkage (TS) during second-line targeted therapy after first-line tyrosine kinase inhibitor (TKI) 
failure on metastatic renal cell carcinoma (mRCC) prognosis. 
Methods: Fifty-two patients were enrolled. The magnitude of TS was assessed according to the 
Response Evaluation Criteria in Solid Tumors v. 1.1, and evaluated as a continuous variable and by 
categorical classification: good responders (≥ -30%), mild responders (-0.1% to -29.9%), poor 
responders (0% to +19.9%), and non-responders (≥ +20% or new lesions). Overall survival (OS) and 
progression-free survival (PFS) after second-line therapy initiation were evaluated according to the 
categorical classification. Factors predicting OS and PFS were also examined.  
Results: The mean magnitude of TS was -1.29%, and there were 9, 21, 11, and 11 good responders, 
mild responders, poor responders, and non-responders, respectively. The OS and PFS significantly 
improved as the magnitude of TS increased according to the categorical classification (OS: not 
reached, 27.8, 18.2, and 4.67 months; PFS: 13.4, 8.19, 5.18, and 1.84 months, respectively; 
p<0.0001 for both). For OS, the magnitude of TS was not demonstrated as an independent indicator 
in the multivariate analysis (p=0.0872 for the categorical classification, p=0.133 for the continuous 
variable) whereas for second –line PFS, the magnitude of TS according to both the categorical 
classification and continuous variable was found to be an independent factor in the multivariate 
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analysis (p<0.0001 for both).  
Conclusions: The magnitude of TS is an independent predictive factor for PFS, and may represent a 
surrogate marker for OS. 
 
Mini-abstract: We demonstrated that the magnitude of best tumor shrinkage during second-line 
targeted therapy was an independent predictive factor for progression-free survival, and may 
represent a surrogate marker for overall survival. 
 
Key words: Molecular targeted therapy, Renal cancer, Prognosis, Response Evaluation Criteria in 
Solid Tumors 
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Introduction 
Molecular targeted therapy (TT) is a mainstay of treatment of metastatic renal cell carcinoma 
(mRCC) patients; it has been demonstrated to improve patient survival, including progression-free 
survival (PFS) and overall survival (OS), compared with cytokine therapy. In mRCC, TT aimed at 
inhibiting the vascular endothelial growth factor (VEGF) or mammalian target of rapamycin 
(mTOR) pathways is currently being used. The majority of patients with good or intermediate risk 
according to the Memorial Sloan-Kettering Cancer Center (MSKCC) criteria are commonly treated 
with a tyrosine kinase inhibitor (TKI), particularly sunitinib, as first-line therapy, based on the results 
of previous randomized clinical trials (1, 2). In cases of failure of the first-line therapy, second-line 
treatment is generally administered. However, it remains controversial whether a TKI-mTOR 
inhibitor (mTORi) or TKI-TKI combination as sequential treatment provides a better outcome (3, 4).  
As the response and survival rates have improved since the introduction of TT, several studies have 
been performed to indicate the prognostic or predictive indicators for outcome after TT initiation. 
Especially, the objective response, that is, the tumor shrinkage (TS), according to the standard 
Response Evaluation Criteria in Solid Tumors (RECIST), has been regarded as a useful marker for 
outcome (5-8). In most previous studies, the patients were divided into subgroups with several 
ranges of TS to evaluate the survival (5, 6, 8) . However, it should be noted that those data were 
obtained from large clinical trials; hence, the enrolled populations might have had tendencies of 
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being in a better general condition than the mRCC population in the real world. Moreover, some 
patients had been treated with previous cytokine therapy, and the number of studies on second-line 
therapy performed in patients who had previously received only TT is limited. In addition, it remains 
uncertain how the magnitude of TS as a continuous variable affects patient survival.  
With this in mind, the aims of the present study were to investigate the correlations between the 
magnitude of best TS during second-line TT according to the categorical classification and as a 
continuous variable and to determine patient survival after second-line in patients who failed 
first-line TKI treatment, without previous cytokine therapy in the real world. Moreover, we 
compared the magnitude of TS between patients treated with TKIs and mTORis as the second-line 
agent, and investigated how the magnitude of TS could affect the outcomes in these patients. 
 
Patients and methods 
The Internal Ethics Review Board of Tokyo Women’s Medical University approved this 
retrospective study (ID: 3440), which was performed in accordance with the principles outlined in 
the Declaration of Helsinki.  
In our department, between January 2007 and April 2015, overall 77 patients received second-line 
TT after first-line TKI failure, without previous cytokine therapy. Among these 77 patients, 11 
patients who did not receive radical nephrectomy, 7 patients whose reason of shifting to second-line 
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treatment was adverse events of the first-line agent, 3 patients who received hemodialysis therapy, 1 
patient who had undergone prior kidney transplantation, 3 patients who received the second-line TT 
for less than 4 weeks, and 7 patients who did not have detailed imaging data, were excluded. Finally, 
the remaining 52 patients were enrolled in the present study. 
Clinical and laboratory data were extracted from an electronic database and the patient medical 
records. The MSKCC risk at second-line TT initiation was identified according to Motzer’s risk 
classification (9).  
 
Imaging methods and imaging evaluation  
Baseline imaging examination, including plain or contrast-enhanced computed tomography or 
magnetic resonance imaging, of the chest, abdomen, and pelvis, was performed within 28 days 
before the start of a new therapy course. Regular scans were also performed every 4-12 weeks of 
therapy according to the patients’ condition. 
The target lesions were selected based on the baseline imaging results, and evaluated according to 
RECIST v. 1.1 (10). The best TS was defined as the time point with maximum TS (percentage 
change in the sum diameter of all target lesions). Sclerotic osseous lesions were excluded. The 
patients were also stratified into 4 subgroups according to our stratification strategy of the magnitude 
of best TS: good responders (≥ -30%), mild responders (-29.9% to -0.1%), poor responders (0% to 
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+19.9%), and non-responders (≥ +20% or the occurrence of new lesions). The magnitude of TS 
(continuous variable) was defined as the change from baseline (in %) in the target lesions only; we 
ignored the change of the sum diameter of novel lesions in cases of progressive disease (PD) 
according to RECIST v. 1.1 (10). One investigator (H.I.), who was blinded to all other clinical 
parameters and the patient outcomes, performed all image analyses. 
 
Statistical analysis  
OS and PFS after second-line therapy initiation were calculated using the Kaplan-Meier method, 
and compared using the log-rank test according to the above-mentioned subgroups and the 
second-line targeted therapy agents (i.e., TKIs vs. mTORis). The difference in the degree of best TS 
between TKIs and mTORis was compared using the Mann-Whitney U test. We performed univariate 
and multivariate analyses to identify factors associated with OS and PFS using Cox proportional 
hazards regression models based on the best TS during second-line treatment according to the 
above-mentioned subgroup classifications and the continuous variable. A waterfall plot was also 
created to demonstrate the TS differences between TKIs and mTORis. The second-line OS was 
defined as the time from second-line therapy initiation to death from any cause. The first- and 
second-line PFSs were defined as the time from first- and second-line therapy initiation, respectively, 
to the date of progression or death from any cause, whichever came first. Progression was defined 
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based on RECIST v. 1.1 (10) as a 20% increase in sum diameter of the target lesion, with at least a 
5-mm absolute increase, or as appearance of novel metastatic lesions. That is, in spite of the 
definition of the magnitude of TS used in this study, all cases with appearance of novel metastatic 
lesions were diagnosed as PD. Risk was expressed as the hazard ratio (HR) with 95% confidence 
interval (CI). The level of significance was set at p < 0.05. All analyses were performed using the 
JMP® 11 software package (SAS Institute Inc., Cary, NC, USA). 
 
Results 
Patient characteristics  
Table 1 shows the patient characteristics. The majority of patients were male (73.1%), and were 
pathologically diagnosed with clear cell carcinoma (80.8%). The MSKCC risks at second-line 
therapy initiation were classified as favorable, intermediate, and poor in 11 (21.2%), 28 (53.8%), and 
13 (25%) patients, respectively (9). The mean age at second-line initiation was 62.9 years. Previous 
treatments other than TT were performed in 11(21.2%) patients; these included radiation therapy and 
metastasectomy in 9 (17.3%) and 4 (7.7%) patients, respectively, with some overlap. As the first-line 
TKI agent, sunitinib, sorafenib, and pazopanib were used in 27 (51.9%), 24 (46.2%), 1 (1.92%) 
patients, respectively. As second-line therapy, TKIs were used in 37 (71.2%) patients (sunitinib, 9; 
sorafenib, 2; pazopanib, 2; axitinib, 24), while mTORis were used in 15 (28.8%) patients 
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(temsirolimus, 5; evelolimus, 10). The mean first-line PFS was 12.2 months.  
Regarding the magnitude of best TS during first-line treatment, a complete response, partial 
response, stable disease (SD), and PD were found in 2 (3.85%), 12 (23.1%), 34 (65.4%), and 4 
(7.7%) patients, respectively. The mean TS (continuous variable) during first-line treatment was 
-14.1%. The mean follow-up period after second-line therapy initiation was 13.2 months. 
 
Magnitude of best tumor shrinkage during second-line targeted therapy 
As seen in Table 2, the mean magnitude of TS (continuous variable) was -1.29% after second-line 
therapy, and the magnitudes of TS (categorical classification) were as follows: good responders, 9 
(17.3%); mild responders, 21 (40.4%); poor responders, 11 (21.2%); and non-responders, 11 (21.2%). 
TKI and mTORi as second-line agents were administered in 37 (71.2%) and 15 (28.8%) patients, 
and the mean magnitudes of TS were -0.61% and -2.96% respectively. There was no significant 
difference in the magnitude of TS between the different second-line agents (p=0.686) (Table 2). The 
magnitude of TS on target lesions according to the second-line agents is demonstrated by using a 
waterfall plot for individual patients in Fig. 1.  
 
Associations between the magnitude of best tumor shrinkage and patient survival 
 Kaplan-Meier curves revealed statistical significant correlations between the magnitude of best TS 
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and patient survival after second-line therapy initiation (Fig. 2, 3). The OS was significantly higher 
in patients who showed a higher magnitude of TS (median: not reached, 27.8, 18.2, and 4.67 months 
in good responders, mild responders, poor responders, non-responders, respectively, p<0.0001; Fig. 
2). Similarly, the PFS was also significantly higher in patients who showed higher magnitude of TS 
(median: 13.4, 8.19, 5.18, and 1.84 months, respectively, p<0.0001; Fig. 3).  
 
Associations between second-line targeted agents and patient survival 
Figure 4 and 5 show Kaplan-Meier curves of the patient survival after second-line therapy initiation 
according to the use of TKIs or mTORis as the second-line targeted agent. There was no significant 
association between these agents and OS (median: TKI, 16.2 months vs. mTORi, 25.6 months, 
p=0.573; Fig. 4). Similarly, there was no significant association with PFS (median: 5.69 months vs. 
6.68 months, p=0.858; Fig. 5).  
 
Prognostic indicators for patient survival 
For OS, the magnitude of TS with both the categorical classification (p<0.0001) and as a 
continuous variable (HR, 1.03; 95%CI, 1.02-1.05; p<0.0001) was a significant indicator, together 
with first-line PFS (HR, 0.93; 95%CI, 0.86-0.99; p=0.0141) and second-line PFS (HR, 0.71; 95%CI, 
0.58-0.83; p<0.0001) in the univariate analyses. For PFS, the magnitude of TS with both the 
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categorical classification (p<0.0001) and as a continuous variable (HR, 1.04; 95%CI, 1.03-1.06; 
p<0.0001) was a significant indicator, together with the MSKCC risk at second-line treatment 
(p=0.0093), pathology (clear vs. non-clear cell carcinoma; HR 2.54; 95%CI, 1.16-5.16; p=0.0215), 
and first-line PFS (HR, 0.94; 95%CI, 0.89-0.98; p=0.0032) in the univariate analyses.  
In the multivariate analysis, for OS, the magnitude of TS was not an independent prognostic factor 
with the categorical classification (p=0.0872) or as a continuous variable (HR, 1.01; 95%CI, 
1.00-1.03; p=0.133), whereas second-line PFS was found to be an independent factor (HR, 0.79; 
95%CI, 0.65-0.93; p=0.028 for the categorical classification; HR, 0.76; 95%CI, 0.62-0.91; p=0.0012 
for the continuous variable). For PFS, the magnitude of TS was an independent prognostic factor 
according to the magnitude of TS with the categorical classification (p<0.0001) and as a continuous 
variable (HR, 1.04; 95%CI, 1.02-1.06; p<0.0001) (Tables 3, 4). 
 
Discussion  
In the present study, we examined the influence of the best TS during second-line TT on patient 
survival after first-line TKI failure, without prior cytokine therapy. We demonstrated that the 
magnitude of best TS was an independent predictive factor for PFS but not OS after second-line 
therapy initiation according to the categorical classification and as a continuous variable, and that 
second-line PFS was an independent indicator for OS. Moreover, we demonstrated no significant 
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difference was observed in either the magnitude of TS or patient survival in patients who received 
TKIs and those who received mTORis as the second-line agent after first-line TKI failure.  
As PFS showed a significant correlation with the magnitude of TS, we should choose an agent 
associated with a high magnitude of TS for improving PFS. Meanwhile, for OS, we found that PFS, 
rather than the magnitude of TS, was an independent predictive factor. Hence, as PFS cannot easily 
be predicted during treatment in clinical practice, we believe that the magnitude of TS may represent 
a useful surrogate marker for OS after second-line therapy initiation; to some extent, realization of 
the magnitude of TS could help us to predict OS. Halabi et al. also demonstrated a high dependence 
between PFS and OS, suggesting that PFS may be used as a surrogate endpoint for OS in patients 
with mRCC (11). 
Several studies have previously been performed to investigate the prognostic factors for mRCC 
patients after TT introduction. The objective response has been already identified as a useful marker, 
with the ‘initial’ or ‘best’ TS being a significant indicator for mRCC outcomes during first-line 
therapy (5-8, 12) . Recently, a large-size retrospective study indicated that the magnitude of best TS 
during second-line therapy could also be regarded as an effective prognostic factor in addition to that 
during first-line therapy (8). Grünwald et al. (8) described that patient survival showed a clear and 
significant proportional relationship to the degree of TS during second-line treatment; the OS and 
PFS were significantly higher as the magnitude of TS increased in all subgroups. Meanwhile, our 
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results revealed no significant difference in patient survival between the mild responder and poor 
responder subgroups (data not shown), which were originally categorized as “SD” according to 
RECIST (10). This discrepancy may be caused by differences in the cohort sizes or by confounding 
factors due to differences in the patients’ background between the studies. 
Furthermore, the present study also indicated that the magnitude of TS seemed to be lower during 
second-line than first-line therapy (-1.29% vs. -14.1%, p=0.0861, Mann-Whitney U test). This result 
was similar to that of an analysis of 103 mRCC patients who received triple-sequence therapies (4); 
this previous study indicated that the degrees of TS during second- and 3rd-line therapies were lower 
than those during first-line treatment (4). In other words, the rates of patients with PD and SD were 
higher than the corresponding rates during first-line therapy. This suggests that the effectiveness of 
second-line TT may be lower compared with that of first-line treatment. Moreover, other studies 
have previously demonstrated that resistance to VEGF-inhibitor (VEGFi) during first-line therapy 
strongly associated with poor clinical outcomes (3, 13, 14). For second-line therapy, a similar 
tendency was noted in our study; the patients who were refractory to second-line therapy showed a 
relatively poor survival compared with the other subgroups (Fig. 2, 3).  
Powerful evidence for the appropriate strategy of sequential second-line therapy is lacking. Bush et 
al. (3) suggested that there was no significant difference in the efficacy between TKIs and mTORis 
as second-line TT following first-line TKI failure. Our results were similar in terms of the efficacy of 
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TKIs or mTORis as second-line treatments; that is, the second-line agent was not associated with 
patient survival after second-line therapy initiation. However, it should be noted that these results 
could be affected by considerable bias; most patients who had a lower degree of TS and poorer 
outcome received sorafenib as the first-line TKI agent and were sequentially treated with sunitinib as 
second-line therapy (data not shown). This was because sunitinib had not been approved by the 
insurance system in Japan at the time of the study. Therefore, we should investigate the differences 
in magnitude of TS and effectiveness between TKIs, such as axitinib, and mTORis, such as 
everolimus, after first-line sunitinib failure in the future. 
There are several limitations of our study. First, the major limitation is the small number of patients, 
which makes it difficult to extrapolate the results to the general mRCC patient population. Therefore, 
our results should be confirmed by a larger and more detailed study. Second, we did not consider the 
withdrawal period and/ or dose changes of TT caused by the adverse events, and the true duration 
and/ or density of treatment was hence not assessed. Third, as the timing of imaging evaluation was 
irregular (every 1 to 3 months), there was an unavoidable time lag in the patients’ survival. 
Meanwhile, we believe that the homogeneous patient backgrounds, with all patients undergoing 
prior radical nephrectomy and receiving first-line TKI therapy, are some of the main advantages of 
the present study. Moreover, the strongest point of our study is that we evaluated only patients who 
had not been treated with prior cytokine therapy. To our knowledge, this is the first study suggesting 
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the prognostic ability of the magnitude of TS during second-line therapy on patient survival in 
mRCC patients without prior cytokine treatment.  
 In conclusion, the present study demonstrated that the magnitude of best TS was an independent 
predictive factor for PFS, and that it might represent a surrogate marker for OS. Moreover, no 
significant differences in the effectiveness of TKIs and mTORis as second-line therapy after 
first-line TKI failure were observed. As there are only a limited number of studies that have 
demonstrated significant correlations between the magnitude of TS and patient outcome, including 
PFS and OS, in the real world setting, especially for second-line therapy, the present study may 
enable more effective prediction of patient outcome by evaluating the magnitude of TS. Meanwhile, 
further studies are warranted to identify novel prognostic biomarkers and imaging findings, as well 
as the appropriate regimens of sequential therapies for mRCC in order to improve the clinical 
outcomes of this malignancy.  
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Figure legends  
Fig. 1 Waterfall plot showing the magnitude of best tumor shrinkage according to the second-line 
agent used in each patient, with comparisons of tyrosine kinase inhibitors (TKIs) (n=37) and 
mammalian target of rapamycin inhibitors (mTORis) (n=15)  
 
Fig. 2 Overall survival after second-line targeted therapy initiation according to the magnitude of 
best tumor shrinkage (TS) during second-line therapy (categorical classification) 
The survival rate was calculated by the Kaplan-Meier method, and statistical significance was 
compared using the log-rank test (p<0.0001).   
 
Fig. 3 Progression-free survival after second-line targeted therapy initiation according to the 
magnitude of best tumor shrinkage (TS) during second-line therapy (categorical classification) 
The survival rate was calculated by the Kaplan-Meier method, and statistical significance was 
compared using the log-rank test (p<0.0001). 
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Fig. 4 Overall survival after second-line targeted therapy initiation according to the second-line 
agents, with comparisons of tyrosine kinase inhibitors (TKIs) (n=37) and mammalian target of 
rapamycin inhibitors (mTORis) (n=15) 
The survival rate was calculated by the Kaplan-Meier method, and statistical significance was 
compared using the log-rank test (p=0.573). (p=0.573). 
 
Fig. 5 Progression-free survival after second-line targeted therapy initiation according to the 
second-line agents, with comparisons of tyrosine kinase inhibitors (TKIs) and mammalian target of 
rapamycin inhibitors (mTORis) 
The survival rate was calculated by the Kaplan-Meier method, and statistical significance was 
compared using the log-rank test (p=0.858). 
   
Figure 1: Magnitudes of best tumor shrinkage with TKIs and mTORis as 2nd-line agents
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Figure 2: Overall survival after 2nd-line targeted therapy initiation according to the 
magnitude of best TS during 2nd-line targeted therapy
Median (months)
Not reached
27.8
18.2
4.67
Good responder (n=9)
Mild responder (n=21)
Poor responder (n=11)
Non-responder (n=11)
Magnitude of best TS 
Log-rank      p<0.0001
Figure 3: Progression-free survival after 2nd-line targeted therapy initiation 
according to the magnitude of best TS during 2nd-line targeted therapy
Median (months)
13.4
8.19
5.18
1.84
Good responder (n=9)
Mild responder (n=21)
Poor responder (n=11)
Non-responder (n=11)
Magnitude of best TS  
Log-rank      p<0.0001
Figure 4: Overall survival after 2nd-line targeted therapy initiation according to the 
2nd-line agents 
Agents Median (months)
TKI (n=37)
mTORi (n=15)
16.2
25.6
Log-rank      p=0.573
Figure 5: Progression-free survival after 2nd-line targeted therapy initiation 
according to the 2nd-line agents
Agents Median (months)
TKI (n=37)
mTORi (n=15)
5.69
6.68
Log-rank      p=0.858
Table 1: Patient characteristics   
Characteristics Total (n=52) 
Sex 
 Male/ female 
 
38 (73.1%)/ 14 (26.9%) 
Mean age at 2
nd
-line therapy initiation , years (median, range) 62.9 (64.0, 29-87) 
MSKCC risk at 2
nd
-line therapy initiation  
 Favorable 
 Intermediate 
 Poor 
 
11 (21.2%) 
28 (53.8%) 
13 (25%) 
Previous treatments other than targeted therapy for metastatic lesions  
 Yes / no 
  Radiation 
  Metastasectomy 
 
11 (21.2%)/ 41 (78.8%) 
9 (17.3%) 
4 (7.7%) 
Pathology 
 CCC/ non-CCC 
 
42 (80.8%)/ 10 (19.2%) 
Best TS during 1
st
-line therapy according to RECIST 
 CR 
 PR 
 SD 
 PD 
 
2 (3.85%) 
12 (23.1%) 
34 (65.4%) 
4 (7.7%) 
Mean magnitude of best TS during 1
st
-line therapy, % (median, range) -14.1% (-11.7%, -100% to +55.0%) 
Mean 1
st
-line PFS , months (median, range) 12.2 (8.78, 2.01 to 47.8) 
TKIs used as 1
st
-line therapy 
 Sunitinib  
 Sorafenib 
 Pazopanib  
 
27 (51.9%) 
24 (46.2%) 
1 (1.92%) 
Agents used as 2
nd
-line therapy 
 TKI  
  Sunitinib 
  Sorafenib 
  Pazopanib  
  Axitinib  
 mTORi 
  Temsirolimus 
  Everolimus  
 
37 (71.2%) 
9 (17.3%) 
2 (3.85%) 
2 (3.85%) 
24 (46.2%) 
15 (28.8%) 
5 (9.62%) 
10 (19.2%) 
Mean follow-up period after 2
nd
-line therapy initiation , months (median, range) 13.2 (10.2, 2.04 to 48.1) 
MSKCC, Memorial Sloan-Kettering Cancer Center; CCC, clear cell carcinoma; TS, tumor shrinkage; RECIST, 
Response Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial response; SD, stable disease; PD, 
progression disease; PFS, progression-free survival; TKI, tyrosine kinase inhibitor; mTORi, mammalian target of 
rapamycin inhibitor  
 
 
Table 2: Magnitudes of best TS during 2
nd
-line targeted therapy 
 All (n=52) TKI (n=37) mTORi (n=15) p  
Categorical classification      
 Good responder 9 (17.3%) 6 (16.2%) 3 (20.0%)  
 Mild responder  21 (40.4%) 14 (37.8%) 7 (46.7%)  
 Poor responder 11 (21.2%) 9 (24.3%) 2 (13.3%)  
 Non-responder  11 (21.2%) 8 (21.6%) 3 (20.0%)  
Mean, % (median, range) -1.29% (-3.30%, -100% to +111.2%) -0.61% (-1.57%, -100% to +111.2%) -2.96 % (-5.89%, -48.2 % to +80.1 %) 0.686 
TS, tumor shrinkage; TKI, tyrosine kinase inhibitor; mTORi, mammalian target of rapamycin inhibitor  
 
 
Table 3: Univariate and multivariate analyses of predictors for 2
nd
-line OS 
Variable 
 
Univariate  Multivariate (categorical classifications)  Multivariate (continuous variable)  
 HR (95% CI) p HR (95% CI) p HR (95% CI) P 
MSKCC risk at 2
nd
-line therapy initiation  
 Favorable  
 Intermediate 
 Poor 
 
0.65 (0.15-2.04) 
Reference 
2.09 (0.82-5.04) 
0.153 
0.485 
- 
0.118 
    
Previous treatment other than targeted therapies  
 Yes 
 No  
 
Reference 
0.95 (0.35-3.32) 
 
- 
0.925 
    
Pathology 
 CCC 
 Non-CCC 
 
Reference 
1.74 (0.77-3.99) 
 
- 
0.179 
    
Magnitude of best TS during 1
st
-line therapy according to RECIST 
 CR 
 PR 
 SD 
 PD 
 
4.87 (0-3.42) 
0.73 (0.24-1.89) 
Reference 
1.11 (0.26-3.36) 
0.658 
0.274 
0.532 
- 
0.867 
    
Magnitude of best TS during 1
st
-line therapy (continuous variable) 1.01 (0.99-1.03) 0.226     
1
st
-line PFS  0.93 (0.86-0.99) 0.0141 0.97 (0.88-1.06) 0.557 0.98 (0.91-1.05) 0.581 
TKIs used as 1
st
-line therapy 
 Sunitinib  
 Sorafenib and pazopanib 
 
Reference 
1.74 (0.77-3.99) 
 
- 
0.179 
    
Agents used as 2
nd
-line therapy 
 TKI   
 mTORi  
 
Reference 
0.77 (0.30-1.84) 
 
- 
0.570 
    
Magnitude of best TS during 2
nd
-line therapy (categorical classification) 
 Good responder 
 Mild responder   
 Poor responder 
 Non-responder  
 
0.19 (0.010-1.03) 
Reference 
2.08 (0.68-6.12) 
18.6 (5.06-81.6) 
<0.0001 
0.0556 
- 
0.192 
<0.0001 
 
0.63 (0.031-4.30) 
Reference 
0.84 (0.22-3.17) 
4.86 (1.09-25.4) 
0.0872 
0.673 
- 
0.794 
0.0381 
- - 
Magnitude of best TS during 2
nd
-line  therapy (continuous variable) 1.03 (1.02-1.05) <0.0001 - - 1.01 (1.00-1.03) 0.133 
2
nd
-line PFS  0.71 (0.58-0.83) <0.0001 0.79 (0.65-0.93) 0.0028 0.76 (0.62-0.91) 0.0012 
OS, overall survival; HR, hazard ratio; CI, confidence interval; MSKCC, Memorial Sloan-Kettering 
Cancer Center; CCC, clear cell carcinoma; TS, tumor shrinkage; RECIST, Response Evaluation 
Criteria in Solid Tumors; CR, complete response; PR, partial response; SD, stable disease; PD, 
progression disease; PFS, progression-free survival; TKI, tyrosine kinase inhibitor; mTORi, 
mammalian target of rapamycin inhibitor  
 
 
Table 4: Univariate and multivariate analyses of predictors for 2
nd
-line PFS 
Variable 
 
Univariate  Multivariate (categorical classifications)  Multivariate (continuous variable)  
 HR (95% CI) p HR (95% CI) p HR (95% CI) p 
MSKCC risk at 2
nd
-line therapy initiation  
 Favorable  
 Intermediate 
 Poor 
 
0.47 (0.17-1.09) 
Reference 
2.08 (1.00-4.16) 
0.0093 
0.0790 
- 
0.0503 
 
0.50 (0.17-1.29) 
Reference 
1.02 (0.44-2.27) 
0.322 
0.155 
- 
0.959 
 
0.56 (0.20-1.37) 
Reference 
1.13 (0.50-2.44) 
0.374 
0.214 
- 
0.756 
Previous treatment other than targeted therapies  
 Yes 
 No  
 
Reference 
0.75 (0.37-1.68) 
 
- 
0.465 
    
Pathology 
 CCC 
 Non-CCC 
 
Reference 
2.54 (1.16-5.16) 
 
- 
0.0215 
 
Reference 
1.22 (0.53-2.65) 
 
- 
0.628 
 
Reference 
0.99 (0.41-2.23) 
 
- 
0.978 
Magnitude of best TS during 1
st
-line therapy according to RECIST 
 CR 
 PR 
 SD 
 PD 
 
0.44 (0.025-2.10) 
0.61 (0.28-1.23) 
Reference 
2.28 (0.67-5.98) 
0.168 
0.364 
0.172 
- 
0.169  
    
Magnitude of best TS during 1
st
-line therapy (continuous variable) 1.01 (1.00-1.03) 0.0593     
1
st
-line PFS  0.94 (0.89-0.98) 0.0032 1.00 (0.94-1.04) 0.844 0.98 (0.94-1.03) 0.434 
TKIs used as 1
st
-line therapy 
 Sunitinib  
 Sorafenib and pazopanib 
 
Reference 
1.04 (0.57-1.88) 
 
- 
0.902 
    
Agents used as 2
nd
-line therapy 
 TKI   
 mTORi  
 
Reference 
0.94 (0.47-1.78) 
 
- 
0.858 
    
Magnitude of best TS during 2
nd
-line therapy (categorical classification) 
 Good responder 
 Mild responder   
 Poor responder  
 Non-responder  
 
0.49 (0.16-1.24) 
Reference 
3.05 (1.23-7.49) 
52.4 (13.9-263.9) 
<0.0001 
0.136 
- 
0.0167 
<0.0001 
 
0.41 (0.13-1.13) 
Reference 
2.15 (0.77-6.10) 
38.9 (9.60-210.2) 
<0.0001 
0.0868 
- 
0.142 
<0.0001 
- - 
Magnitude of best TS during 2
nd
-line  therapy (continuous variable) 1.04 (1.03-1.06) <0.0001 - - 1.04 (1.02-1.06) <0.0001 
PFS, progression free survival; HR, hazard ratio; CI, confidence interval; MSKCC, Memorial Sloan-
Kettering Cancer Center; CCC, clear cell carcinoma; TS, tumor shrinkage; RECIST, Response 
Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial response; SD, stable 
disease; PD, progression disease; TKI, tyrosine kinase inhibitor; mTORi, mammalian target of 
rapamycin inhibitor 
 
